Curated News
By: NewsRamp Editorial Staff
February 25, 2026

Scinai Secures Key Grant for Robotic Manufacturing, Boosting CDMO Strategy

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Scinai Immunotherapeutics gains a competitive edge with NIS 5 million in non-dilutive funding to enhance its sterile biologics manufacturing capabilities and CDMO expansion.
  • Scinai's project involves acquiring and validating a robotic aseptic fill & finish system to meet EU GMP standards, with completion targeted for Q3 2026.
  • This advancement in automated sterile manufacturing helps ensure safer, more reliable production of biologics, potentially improving patient access to critical treatments worldwide.
  • Scinai is deploying robotic arms for sterile drug filling, a cutting-edge approach that minimizes contamination risks in biopharmaceutical production.

Impact - Why it Matters

This development matters because it directly strengthens the infrastructure for producing advanced biologic drugs, which are increasingly critical for treating complex diseases like cancers, autoimmune disorders, and rare conditions. By enhancing sterile manufacturing capabilities with automated, EU-standard robotics, Scinai is positioning itself as a more reliable and scalable partner for biotech companies. This reduces development risks and potential delays for novel therapies, ultimately accelerating their path to patients. For the biopharma ecosystem, such investments in advanced manufacturing are essential to meet growing demand for biologics and ensure supply chain resilience. For investors, the disciplined use of non-dilutive funding demonstrates prudent capital management while funding growth.

Summary

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company with a contract development and manufacturing organization (CDMO) and an immunology R&D pipeline, has secured a significant boost for its manufacturing expansion. The Israel Innovation Authority has approved expanded support for the company's project to advance a robotic aseptic fill & finish platform, allowing Scinai to utilize the full approved grant budget of NIS 5 million (approximately $1.35 million) over two years. Crucially, about 66% of this funding is non-dilutive, meaning it does not require issuing new shares and thus protects existing shareholder value. This program supports the acquisition and validation of a fully automated robotic-arm system aligned with stringent EU GMP Annex 1 standards, with validation targeted for completion by the third quarter of 2026.

This investment is a key component of Scinai's broader CDMO expansion strategy, which was significantly bolstered by its recent acquisition of Recipharm Israel Ltd. and the establishment of a strategic commercial collaboration with the global Recipharm network. This move strengthens Scinai's integrated two-site manufacturing platform in Israel—comprising a biologics facility in Jerusalem and a small-molecule API site in Yavne—and enhances its sterile biologics capabilities. The robotic system will support external clients from preclinical development through Phase I/II clinical supply, offering services like biologics process development, analytical method development, and sterile fill and finish. The collaboration with Recipharm provides clients a defined pathway from early clinical development to late-stage and commercial manufacturing within a global network, aiming to ensure continuity, streamline tech transfer, and reduce scale-up risks.

In parallel to its CDMO operations, Scinai is advancing a focused immunology R&D pipeline. This includes PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs for inflammation. The company is actively seeking strategic partnerships and licensing opportunities to advance these programs. The latest news and updates relating to SCNI are available in the company's newsroom, and this announcement was distributed via BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on biotechnology and life sciences sectors, providing enhanced press release distribution and corporate communications solutions.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Secures Key Grant for Robotic Manufacturing, Boosting CDMO Strategy

blockchain registration record for this content.